Latest Cell Genesys Stories
Randomized Phase 2 Study of Docetaxel and Prednisone With or Without OGX-011 in Patients With Metastatic Castration-Resistant Prostate Cancer. Chi K.N., et al. JCO Sep 20, 2010: 4247-4254 BOTHELL, WA and VANCOUVER, Sept. 22 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, Inc.
SOUTH SAN FRANCISCO, Calif., March 5 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc.
TUSTIN, Calif., Oct. 21 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHMD) today reported positive results from its Phase II trial evaluating bavituximab in combination with docetaxel in patients with advanced breast cancer.
NEW YORK, Sept.
- New Progression-Free Survival Data Support Picoplatin in Combination with Docetaxel/Prednisone as First-Line Therapy for Metastatic Castration-Resistant Prostate Cancer - - Results To Be Presented at the American Society of Clinical Oncology's 2009 Genitourinary Cancers Symposium - SOUTH SAN FRANCISCO, Calif., Feb.
Cell Genesys, Inc. (Nasdaq:CEGE) today reported financial results for the third quarter ended September 30, 2008.
SOUTH SAN FRANCISCO, Calif. and GENEVA, Oct. 22 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc.
Cell Genesys, a biotechnology company, has terminated the Vital-1 Phase III clinical trial of Gvax immunotherapy in patients with asymptomatic metastatic hormone-refractory prostate cancer.
- A ceramic container used inside a fuel-fired kiln to protect pots from the flame.